Pharmacology involves studying the actions of drugs and chemicals on cells, tissues and the whole body. It includes finding out how drugs produce beneficial and adverse effects, with the aim of improving the way drugs are tested and to give greater benefit in the treatment of disease. The cellular and chemical abnormalities of disease states are studied in the expectation that molecules may be designed specifically to correct the abnormality. The study of pharmacology requires understanding of normal body functions (biochemistry and physiology) and the disturbances that occur (pathology).

Pharmacology is the basis for much of the research and development of new drugs. The future of pharmacology is assured, as there remain many diseases for which neither cure nor palliation have been devised - for example, Alzheimer’s disease, neurodegenerative diseases and many forms of cancer. Even when a cure or treatment is available, few medicines are perfect and the search for better drugs continues. In addition, other scientists such as physiologists, biochemists and psychologists often find a knowledge of pharmacology useful as they use drugs to probe and define the biological systems they are studying.

Toxicology is closely related to pharmacology but specialises in the study of the harmful effects of drugs and other chemicals on biological systems. A toxicologist is trained to examine the nature of these effects, including their cellular, biochemical and molecular mechanisms of action as well as to assess the potential effects on human health and environmental significance of various types of chemical exposures. The variety of potential adverse effects and the diversity of chemicals in the environment make toxicology a very broad science.

In brief, pharmacologists and toxicologists aim to develop a better understanding of the actions of drugs and chemicals on biological systems for the improvement of human and animal health.
The Department of Pharmacology and Clinical Pharmacology was established in 1978 and is situated in the Faculty of Medical and Health Sciences at the University of Auckland’s Grafton Campus.

Pharmacology is one of the five Departments in the School of Medical Sciences. It is involved in the teaching of pharmacology and toxicology to science students as well as in medicine, pharmacy and nursing programmes. It has many active research programmes in recently renovated modern laboratories in diverse areas of biomedical research.

Sources of support from outside the University include:

- Health Research Council
- Cancer Society of New Zealand
- NZ Neurological Foundation
- National Heart Foundation
- National Child Health Research Foundation
- Lotteries Health Board
- Auckland Medical Research Foundation
- The Wellcome Trust
- The Marsden Fund
- Maurice and Phyllis Paykel Trust
Head of Department and Associate Professor in Toxicology
Malcolm Tingle
PhD Liverpool
Phone: +64 9 923 4949
Room: 503-302H
Email: m.tingle@auckland.ac.nz

Professor in Pharmacology
Bronwen Connor
PhD Auckland
Phone: +64 9 923 3037
Room: 501-501D
Email: b.connor@auckland.ac.nz

Professor in Pharmacology
Michael Dragunow
PhD Otago
Phone: +64 9 923 6403
Room: 503-501G
Email: m.dragunow@auckland.ac.nz

Professor in Clinical Pharmacology
Nicholas Holford
MSc MBChB Manc, MRCP(UK), FRACP
Phone: +64 9 923 6730
Room: 503-302A
Email: n.holford@auckland.ac.nz

Professor in Clinical Pharmacology
Mark McKeage
MBChB Otago MMedSci, PhD London FRACP
Phone: +64 9 923 7322
Room: 504-236A
Email: m.mckeage@auckland.ac.nz

Professor in Clinical Anaesthesia
Brian Anderson
MB ChB (Otago), PhD, (Auckland), FANZCA, FCICM
Phone: +64 9 923 6730
Room: 503-302A
Email: briana@adhb.govt.nz
<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Phone</th>
<th>Room</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Professor in Pharmacology</td>
<td>Debbie Young</td>
<td>+64 9 923 4491</td>
<td>502-501C</td>
<td><a href="mailto:ds.young@auckland.ac.nz">ds.young@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Lecturer in Clinical Pharmacology</td>
<td>Catherine Han</td>
<td>TBA</td>
<td>TBA</td>
<td><a href="mailto:c.han@auckland.ac.nz">c.han@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Lecturer in Pharmacology</td>
<td>Jack Flanagan</td>
<td>+64 9 923 9728</td>
<td>504-119</td>
<td><a href="mailto:j.flanagan@auckland.ac.nz">j.flanagan@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Lecturer in Pharmacology</td>
<td>Stephen Jamieson</td>
<td>+64 9 923 9141</td>
<td>504-001</td>
<td><a href="mailto:s.jamieson@auckland.ac.nz">s.jamieson@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Lecturer in Pharmacology</td>
<td>Jacqueline Hannam</td>
<td>+64 9 923 2869</td>
<td>503-302</td>
<td><a href="mailto:j.hannam@auckland.ac.nz">j.hannam@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Lecturer in Pharmacology</td>
<td>Raewyn Poulsen</td>
<td>+64 9 923 3983</td>
<td>502-201</td>
<td><a href="mailto:r.poulsen@auckland.ac.nz">r.poulsen@auckland.ac.nz</a></td>
</tr>
<tr>
<td>Senior Research Fellow</td>
<td>Natasha Grimsey</td>
<td>+64 9 923 1886</td>
<td>503-501F</td>
<td><a href="mailto:n.grimsey@auckland.ac.nz">n.grimsey@auckland.ac.nz</a></td>
</tr>
</tbody>
</table>
Senior pharmacology tutors and professional teaching fellows

Liam Anderson
BTech, PGDip Forensic
Phone: +64 9 923 6037
Room: 501-002
Email: l.anderson@auckland.ac.nz

Deanna Bell
PhD Auckland
Phone: +64 9 923 6950
Room: 501-002
Email: d.bell@auckland.ac.nz

Rachel Cameron
PhD Auckland
Phone: +64 9 923 3186
Room: 501-002
Email: r.cameron@auckland.ac.nz

Leslie Schwarcz
PhD Eugene
Phone: +64 9 923 3715
Room: 501-002
Email: l.schwarcz@auckland.ac.nz
Teaching Technicians

**Gabriella Blidarean**
MSc Romania

**Phone:** +64 9 923 5058  
**Room:** 502-361  
**Email:** g.blidarean@auckland.ac.nz

**Hayley Edwards**
BSc Auckland

**Phone:** +64 9 923 6576  
**Room:** 502-361  
**Email:** hayley.edwards@auckland.ac.nz

Administrative Staff

**Kavita Hussein**
Group Services Team Leader

**Phone:** +64 9 923 6733  
**Room:** 505-1D24  
**Email:** k.hussein@auckland.ac.nz
Areas of research interest

Anticancer drugs

Prof McKeage, Assoc Prof Tingle and Dr Jamieson.

Cancer is the most common cause of death between the ages of 30 to 60. Chemotherapy has emerged as a form of cancer treatment which, although it may have very disagreeable side effects, has dramatically improved survival for some cancers, particularly in children. More effective and less toxic drugs are required. New drugs have been developed locally in the Auckland Cancer Society Research Centre and collaborative research is under way into their fate (i.e. absorption, distribution, metabolism and excretion) in various animal models and in human subjects, the construction of concentration-effect models, tumour-targeted drug delivery and action, mechanisms of toxicity, and the extrapolation of these results to patients for more effective therapy and fewer adverse drug reactions.

Clinical pharmacology

Dr Hannam and Prof Anderson

Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs guides their usage in the clinical setting. For many drugs in anaesthesia, our knowledge on how the PK and PD change in certain subpopulations is limited. Examples of such groups include neonates and cardiac patients. Improving PK and PD models that describe the time course of drug action in these groups can assist with optimising dosing schedules. Dr Hannam and Prof Anderson have an interest in the application of PKPD models to improve dosing of anaesthetics and analgesics for combinations of drugs given concomitantly, and in dosing of common antibiotics. Dr Hannam is also involved in clinical trials investigating differences in drug pharmacology, as well as projects focused on patient safety and the use of large amounts of routinely collected health data to answer research questions on postoperative health outcomes.

Cancer clinical pharmacology

Prof McKeage and Dr Han

We are a research group of eight staff and students working on translational and clinical projects concerned with the clinical pharmacology and development of anticancer drugs. Our group mission is to reduce suffering and mortality from cancer by generating pharmacological knowledge about new and existing anticancer drugs for ultimate use in their clinical applications.

Current research projects are exploring novel DMXAA-based drug combinations, chemotherapy-induced peripheral neuropathy and novel anticancer drugs in phase I trials.

Cancer preclinical pharmacology

Dr Jamieson

Our research focusses on the preclinical development of novel anticancer drugs, including hypoxia-activated prodrugs, molecularly targeted agents and immunotherapies. We utilise in vitro and in vivo models of human cancer to investigate drug pharmacokinetics and pharmacodynamics as well as testing for anticancer efficacy. To assist this, we are developing new clinically relevant tumour models using patient-derived tumour specimens and early passage human tumour cell lines. Finally, through collaborations with researchers at the Auckland Cancer Society Research Centre, we are using whole genome CRISPR/Cas9 screening
technology to identify predictive biomarkers for novel and established anticancer drugs and to better understand mechanisms of action and resistance.

**Paediatric pharmacology**

**Prof Holford and Prof Anderson**

Prof Holford works with Prof Anderson at Starship Hospital on the clinical pharmacology of medicines in babies and children. The focus of the work is to understand how the changing size and maturation of organ function can be used to predict pharmacokinetic and pharmacodynamic properties of medicines; much of this work has centred on drugs commonly used in anaesthesia and intensive care medicine. These data are then used to create practical dosing guidelines for babies ranging from very premature to full term and then for infants and children. Some data is collected at Starship Hospital but most of the analysis relies on collaboration with paediatricians overseas.

**Disease progress and drug action**

**Prof Holford**

Clinical pharmacology expresses the combined knowledge of disease and how drugs affect it. We are turning our attention towards understanding how drugs affect the long-term progression of disease. Dr Holford is engaged in studies of Parkinson’s Disease and Alzheimer’s Disease, osteoporosis, depression and HIV/AIDS which describe both the effects of drugs and the natural progression of the disease over time.

**Drug metabolism and toxicology**

**Assoc Prof Tingle**

Nearly every drug undergoes some sort of metabolism in the body. This is important for duration of drug action. The toxicity of drugs often involves metabolism, either through a lack of metabolism resulting in higher than expected concentrations or conversion to a chemically-reactive metabolite. Such reactive intermediates may interact with critical macromolecules to initiate direct toxicity (cell death), genotoxicity or hypersensitivity reactions. There may be considerable variability in metabolism between humans and across species, in particular the expression and activity of metabolizing enzymes that may in turn influence the toxicity of drugs and environmental toxicants. Research is focussed on investigating drug metabolism in humans (patients or volunteers) and modelling such metabolism using in vitro and in vivo approaches to probe the role this may play in drug toxicity.

**New therapies for brain diseases**

**Assoc Prof Young**

This group is interested in understanding disease mechanisms and developing novel therapeutic strategies for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s disease, stroke and epilepsy. Key research areas in the lab include gene therapy and vaccine/antibody-based therapeutic approaches, understanding how environment affects brain structure and function, developing neurodegenerative disease models and optimising viral vector-mediated gene transfer technology. The research covers the full spectrum from molecular biology through to animal behaviour, with the aim being to advance promising approaches to human clinical trials.

**Neural reprogramming and repair**

**Prof Connor**

The laboratory of Neural Reprogramming and Repair focuses predominantly on developing new medicines and therapeutic strategies to treat disorders of the brain that involve brain cell death such as Parkinson’s disease, Huntington’s disease, head injury and stroke. Research is being undertaken to develop novel treatment strategies to prevent cell death, replace lost brain cells and
reduce clinical symptoms of neurological disease and brain injury using techniques such as gene delivery and stem cell therapy. In particular, we use cell reprogramming technology to generate brain stem cells from patient-derived skin cells to model neurological diseases. This technology is used to study disease pathology in living human brain cells as well as identify and screen new drug targets.

**Human neurodegeneration research**

**Prof Dragunow**

Professor Mike Dragunow is a Molecular Pharmacologist and Neuroscientist. Research in his group focuses on molecular mechanisms of human brain neurodegeneration and repair and on developing novel treatments for brain diseases using adult human brain material, tissue microarray, cell culture models (cell lines and primary adult human brain cell cultures), molecular pharmacology and high-content analysis. These combined research tools are being used to understand the causes of human neurodegeneration and to test and develop new treatment strategies.

**Drug discovery**

**Dr Flanagan**

Linking biology to chemistry is our primary area of interest and this involves discovering new compounds that can probe disease biology. For this, disease biology is rendered down to specific molecular and then atomic components. This information is then used to look for ways to stop the function of individual molecules. To do this we exploit the three-dimensional structure of a protein to look for molecules that fit into functionally relevant sites on its surface. Computer based methods broadly classed as molecular modelling are the main tools used. Our predictions are then tested in biochemical experiments, some through collaboration with other researchers, and in this way we can connect theory to experiment. Most of the proteins studied are involved in oncogenic cell signalling pathways including cell surface receptors and the lipid kinase enzymes that link to them.

**Molecular Basis for Disease**

**Dr Poulsen**

Understanding the mechanisms responsible for disease development is important for informing the development of new pharmacological therapies. In many chronic conditions, disease results due to aberrant activity of the cells within the affected tissue. Determining the causes of these changes in cell activity is key for understanding pathology. A major focus of our work is osteoarthritis, the leading cause of disability in adults worldwide but a condition for which there are no disease-modifying pharmacological treatments. Using tissue obtained from patients, we are investigating the pathways involved in disease to identify new potential drug targets. Currently, our research is particularly focussed on the circadian clock, a molecular timekeeping mechanism present within cells that is responsible for scheduling daily cell activity as well as the timing of cell proliferation, differentiation and aging. The circadian clock is altered in cartilage cells in osteoarthritis. Tissue-specific circadian clocks are also altered in a number of chronic conditions such as cancer. We are investigating the causes and consequences of clock disruption in osteoarthritis, and through collaborations, the role of clock disruption in cancer.

**Receptors in Health and Disease**

**Dr Grimsey**

Receptors are specialised proteins that can act like microprocessors to allow the chemical environment outside a cell to have very specific effects on cellular functions. We study G Protein-Coupled Receptors, a large family of which many are already the targets of approved therapeutic drugs. There is huge potential for other receptors to serve as new drug targets and to enhance therapeutic design via a better understanding of
receptor function. We aim to learn more about these fascinating proteins and develop new therapies utilising approaches including drug design, investigating the molecular control of receptor function, and studying what goes wrong with receptor function in disease. A particular area of interest is the cannabinoid system, where we aim to harness the therapeutic potential of chemicals related to cannabis while avoiding psychotropic effects.

Courses and programmes

Undergraduate courses

<table>
<thead>
<tr>
<th>Course</th>
<th>Semester</th>
<th>Title</th>
<th>Prerequisites</th>
<th>Pts</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDSCI 204</td>
<td>S2</td>
<td>Pharmacology and Toxicology</td>
<td>BIOSCI 106 or 107; CHEM 110; MEDSCI 142</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 303*</td>
<td>S1</td>
<td>Drug Disposition and Kinetics</td>
<td>MEDSCI 204</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 304*</td>
<td>S1</td>
<td>Molecular Pharmacology</td>
<td>BIOSCI 203; MEDSCI 204</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 305*</td>
<td>S2</td>
<td>Systems Pharmacology</td>
<td>MEDSCI 204 and 30 points from BIOSCI 203; MEDSCI 203; MEDSCI 205</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 306*</td>
<td>S2</td>
<td>Principles of Toxicology</td>
<td>MEDSCI 204 and 30 points from BIOSCI 203; MEDSCI 203; MEDSCI 205</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 307*</td>
<td>S1</td>
<td>Neuropharmacology</td>
<td>MEDSCI 204. MEDSCI 206</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 318*</td>
<td>S1</td>
<td>Pharmacokinetics and Drug Toxicity</td>
<td>MEDSCI 204 and 30 points from BIOSCI 203; MEDSCI 203; MEDSCI 205</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 319*</td>
<td>S1</td>
<td>Molecular Pharmacology</td>
<td>MEDSCI 204 and 30 points from BIOSCI 203; MEDSCI 203; MEDSCI 205</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 320*</td>
<td>S2</td>
<td>Pharmacology of the Brain and Body</td>
<td>MEDSCI 204 and 30 points from BIOSCI 203; MEDSCI 203; MEDSCI 205; MEDSCI 206</td>
<td>15</td>
</tr>
<tr>
<td>PHARMCOL 399*</td>
<td>S1, S2</td>
<td>Capstone: Integrated Pharmacology</td>
<td>MEDSCI 204 and 30 points from MEDSCI 203, 205, 206, BIOSCI 203, and 30 points from MEDSCI 318-320</td>
<td>15</td>
</tr>
</tbody>
</table>

*These courses will not be offered after 2020

GPA requirements may be in place. Contact the Course Director for further information.
BSc (Majoring in Pharmacology)

Please note that the BSc has been restructured so it is very important that you are aware of which regulations you are enrolled under. If you started your degree programme before the end of 2018, you will be under the old regulations. For all students new to the BSc programme, you will be under the 2019 regulations. The 2019 regulations require that a student must pass a capstone course. There will be transition regulations in place for students who started their BSc in or before 2018 but have not completed by 2020. If you are under transition regulations, have any concerns or require clarification, please contact the Head of Department, Malcolm Tingle.

The Department currently offers one course at stage II (MEDSCI 204 Pharmacology and Toxicology) and five courses at stage III.

1. MEDSCI 303 Drug Disposition and Kinetics
2. MEDSCI 304 Molecular Pharmacology
3. MEDSCI 305 Systems Pharmacology
4. MEDSCI 306 Principles of Toxicology
5. MEDSCI 307 Neuropharmacology

Due to the requirement for a capstone course, the courses offered by the Department of Pharmacology & Clinical Pharmacology will be changing in 2021. There will still be one course at stage II (MEDSCI 204 Pharmacology and Toxicology) and four new courses at stage III.

1. MEDSCI 318 Pharmacokinetics and Drug Toxicity (which will replace MEDSCI 303 & MEDSCI 306)
2. MEDSCI 319 Molecular Pharmacology (which will replace MEDSCI 304)
3. MEDSCI 320 Pharmacology of the Brain and Body (which will replace MEDSCI 305 & MEDSCI 307)
4. PHARMCOL 399 Capstone: Integrated Pharmacology

As part of the changes, the prerequisites for Pharmacology courses are also changing, so be very careful in selecting your stage I & stage II courses. You may find it useful to plan your course selection by seeing what stage III courses interest you and then working back to ensure that you have completed the prerequisite courses.

Regulations for students who began their degree prior to 1 January 2019

A BSc requires 360 points with 300 chosen from a minimum of 3 subjects listed in the BSc schedule.

- At least 180 points must be above Stage I.
- At least 75 points must be obtained from Stage III courses.
- For a single or first major in Pharmacology, you must obtain 30 points from courses MEDSCI 303 and MEDSCI 305 and a further 30 points from MEDSCI 304, 306, and 307.
- A second major must include MEDSCI 303 and 305 and at least 15 points from MEDSCI 304, 306 and 307.
- In addition, a student must pass 30 points from courses offered in the General Education Schedule approved for this degree.
- Up to 30 points may be taken from courses available for other programmes offered at this University

Regulations for students who began their degree after 1 January 2019

A BSc requires 360 points with 300 chosen from a minimum of 3 subjects listed in the BSc schedule.

- At least 180 points must be above Stage I.
- At least 75 points must be obtained from Stage III courses.
- For a single or first major in Pharmacology, you must obtain 15 points from a capstone listed in the BSc schedule and
  - 15 points from BIOSCI 106, CHEM 110
  - 30 points: BIOSCI 107, MEDSCI 142
  - 30 points from BIOSCI 203, MEDSCI 203, 205
  - 15 points MEDSCI 204
  - 30 points MEDSCI 318, 319
  - 15 points from MEDSCI 320, PHARMCOL 399
In addition, a student must pass 30 points from courses offered in the General Education Schedule approved for this degree and the Academic Integrity course as specified in the University Calendar regulations.

Up to 30 points may be taken from courses available for other programmes offered at this University.

See the University Calendar for full regulations and exemptions.

**Students under transition regulations (those who started their BSc in or before 2018 but have not completed by 2020) should contact the HoD for advice.**

**BSc(Hons), PGDipSci, PGDipHSci, MSc or PhD**

Students who have completed a BSc in Pharmacology are able, subject to appropriate grades, to advance to either the one year BSc(Hons) or one year PGDipSci or PGDipHSci programme. The prerequisites are at least 60 points in Stage III Pharmacology with a recommended minimum average grade of B+ for BSc(Hons) and B for PGDipSci. BSc(Hons) students undertake courses (60 points) and a dissertation (60 points). The courses are usually chosen from the 700-level courses listed below. BSc(Hons) is a fast track to PhD. Students with an average grade B- in the PGDipSci or PGDipHSci may proceed to a one year MSc or MHSc by research thesis only (120 points) conditional upon finding a supervisor. Students with good marks in either the BSc(Hons) or MSc programme are able to proceed to a further three years research for a PhD.

**BSc(Hons)**

**Prerequisites:** A BSc degree with at least 60 points in Pharmacology from MEDSCI 303-307, MEDSCI 318-320 and PHARMCOL 399, and at least 90 points at Stage III and a minimum recommended grade of B+.

**Requirements:** BSc(Hons) Dissertation PHARMCOL 787 (60 points) approved by Head of Department plus 60 points from MEDSCI 700-701, MEDSCI 715-723.

**MSc (120 points)**

**Prerequisites:** PGDipSci (in Pharmacology) with an average grade B-, or BSc(Hons).

**Requirements:** MSc Thesis PHARMCOL 796 (120 points).

**MSc (240 points)**

**Prerequisites:** BSc (or approved equivalent) with an average grade (GPA 5.0) in 75 points above Stage II, including at least 45 points in a relevant major.

**Requirements:** 120 points at 700-level with at least 60 points from MEDSCI 700 or 701, MEDSCI 715-723, 735. MSc Thesis PHARMCOL 796 (120 points).

**PGDipSci**

**Prerequisites:** A BSc including at least 45 points from MEDSCI 303-307, MEDSCI 318-320 and PHARMCOL 399 and a minimum recommended grade of B.

**Requirements:** 120 points at 700-level with at least 60 points from MEDSCI 700 or 701, MEDSCI 715-723, 735.
BSc planner

**Stage I**

**Compulsory:**
- BIOSCI 106
- BIOSCI 107
- CHEM 110
- MEDSCI 142

**Strongly recommended:**
- BIOSCI 101

**Stage II**

**Compulsory:**
- MEDSCI 204

**Must take 2 out of 3:**
- BIOSCI 203
- MEDSCI 203
- MEDSCI 205

**Strongly recommended:**
- MEDSCI 206 (especially for MEDSCI 320)

**Stage III**

**Compulsory:**
- MEDSCI 318
- MEDSCI 319

**Must take:**
- MEDSCI 320
- or PHARMCOL 399

**Stage IV**

Not all 700-level courses will be taught every year and you must check their availability with the Department.

<table>
<thead>
<tr>
<th>Course</th>
<th>Semester</th>
<th>Title</th>
<th>Pts</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDSCI 700</td>
<td>S2</td>
<td>Drug Discovery Biology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 701</td>
<td>S1/S2</td>
<td>Special Studies in Medical Science</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 715</td>
<td>S1</td>
<td>Molecular Toxicology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 716</td>
<td>S1</td>
<td>Advanced Drug Disposition and Kinetics</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 717</td>
<td>S1</td>
<td>Advanced Neuroscience: Neuropharmacology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 718</td>
<td>S1</td>
<td>Pharmacology of Anaesthetics &amp; Analgesics</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 719</td>
<td>S2</td>
<td>Pharmacometrics</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 720</td>
<td>S1</td>
<td>Biomedical Research Techniques</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 721</td>
<td>S2</td>
<td>Advanced Toxicology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 722</td>
<td>S2</td>
<td>Clinical Pharmacology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 723</td>
<td>S2</td>
<td>Cancer Pharmacology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 735</td>
<td>S1</td>
<td>Concepts in Pharmacology</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 744</td>
<td>S1/S2</td>
<td>Project Design in Biomedical Sciences</td>
<td>15</td>
</tr>
<tr>
<td>MEDSCI 745</td>
<td>S2</td>
<td>Special Topic: Drug Development</td>
<td>15</td>
</tr>
<tr>
<td>PHARMCOL 787</td>
<td>FY</td>
<td>BSc(Hons) Dissertation</td>
<td>60</td>
</tr>
<tr>
<td>PHARMCOL 796 FY</td>
<td></td>
<td>MSc Thesis in Pharmacology</td>
<td>120</td>
</tr>
</tbody>
</table>
Description of course content

**MEDSCI 204**
**Pharmacology and Toxicology**
Semester Two, three lectures per week and four workshops per semester.
A principles-based introduction to pharmacology and toxicity. Its goals are to impart a working understanding of the nature, applications, and implications of basic pharmacological and toxicological principles as they relate to clinical and biomedical sciences. Topics covered including drug targets and action, ADME and pharmacokinetics, toxicity and adverse drug reactions, preclinical models, drug discovery and development.

**Course Director:** Debbie Young

**Assessment:**
- Coursework: 50%
- Final Exam: 50%

**MEDSCI 303**
**Drug Disposition and Kinetics**
Semester One, two lectures and one laboratory per week.
This is a basic course on the principles of pharmacology. The topics include passage of drugs across membranes, drug absorption, distribution, metabolism and excretion; pharmacokinetics; drug-drug interactions, novel drug delivery systems; mechanisms of drug action; pharmacogenetics and pharmacogenomics; drug analysis and drug dispositions in selected populations, including the elderly, children & neonates, in pregnancy, and in various pathological conditions.

**Course Director:** Malcolm Tingle

**Assessment:**
- Laboratories: 40%
- Mid-semester test: 10%
- Final exam: 50%

**MEDSCI 304**
**Molecular Pharmacology**
Semester One, two lectures and one tutorial per week.
This course explores the cellular and molecular mechanisms of drugs acting at receptors, with a particular focus on G-protein coupled receptors. The lectures explore how receptors signal and traffic through cells and the implications of these processes on drug development and design. The tutorials are designed to support the course material by providing the opportunity to critically evaluate experimental data and learn about experimental methodology and design.

**Course Director:** Jack Flanagan and Raewyn Flanagan

**Assessment:**
- Laboratory write-up/tutorials: 25%
- Laboratory test: 15%
- Mid-semester test: 10%
- Final exam: 50%

**MEDSCI 305**
**Systems Pharmacology**
Semester Two, two lectures and one laboratory per week.
This course considers the modification by drugs of human systems under physiological and pathological conditions. Consideration will be given to the cardiovascular, gastrointestinal, reproductive, respiratory and the central nervous systems. The cellular and molecular mechanisms of action of the drugs are considered.

**Course Director:** Bronwen Connor

**Assessment:**
- Practicals: 25%
- Project: 15%
- Mid-semester test: 10%
- Final exam: 50%
**MEDSCI 306**

**Principles of Toxicology**

**Semester Two, two lectures and one laboratory per week.**

This course introduces the principles and concepts involved in toxicology. The lectures cover the general mechanisms involved in the toxicity of foreign compounds, including the formation and detoxification of chemically reactive metabolites and their interactions with macromolecular targets. The course describes the secondary and tertiary consequences of these interactions, such as direct toxicity, genotoxicity and hypersensitivity reactions, plus the basis of organ-selective toxicity. The toxicity of compounds such as drugs, food additives and contaminants, plant and animal toxins as well as environmental toxicants are included.

**Course Director:** Malcolm Tingle

**Assessment:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mid-semester test</td>
<td>10%</td>
</tr>
<tr>
<td>Project presentation</td>
<td>15%</td>
</tr>
<tr>
<td>Practicals</td>
<td>25%</td>
</tr>
<tr>
<td>Final exam</td>
<td>50%</td>
</tr>
</tbody>
</table>

---

**MEDSCI 307**

**Neuropharmacology**

**Semester One, two lectures and one laboratory per week.**

This course introduces the principles and concepts involved in neuropharmacology. It covers the anatomy, neurochemistry and pharmacology of the normal and diseased human brain; the biochemical causes of psychiatric and neurological diseases; and the types and mechanisms of action of drugs used to treat human brain disorders.

**Course Director:** Mike Dragunow

**Assessment:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mid-semester test</td>
<td>15%</td>
</tr>
<tr>
<td>Laboratories</td>
<td>35%</td>
</tr>
<tr>
<td>Final exam</td>
<td>50%</td>
</tr>
</tbody>
</table>

---

**MEDSCI 318**

**Pharmacokinetics and Drug Toxicity**

Considers the biochemical processes involved in achieving clinically-relevant drug concentrations that result in therapeutic effects and drug toxicity, from drug input, distribution, and elimination plus the ways in which these processes are described (pharmacokinetic modelling). Explores factors such as drug-drug interactions, pharmacogenetics, dosing and pharmacokinetic considerations in selected populations and that may influence both clinical effectiveness and drug toxicity.

**Course Directors:** Jacqui Hannam & Malcolm Tingle

**Assessment:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coursework</td>
<td>50%</td>
</tr>
<tr>
<td>Final exam</td>
<td>50%</td>
</tr>
</tbody>
</table>

---

**MEDSCI 319**

**Molecular Pharmacology**

Explores the cellular and molecular mechanisms of drug action with a focus on G-protein coupled receptors and biochemical targets for cancer therapy. Drug design is considered from the perspective of in silico modelling, biochemical assessment and intracellular signalling.

**Course Director:** Jack Flanagan & Raewyn Poulsen

**Assessment:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coursework</td>
<td>50%</td>
</tr>
<tr>
<td>Final exam</td>
<td>50%</td>
</tr>
</tbody>
</table>

---

**MEDSCI 320**

**Pharmacology of the Brain and Body**

Extends the principles of pharmacology acquired at Stage 2 to discuss how diseases can be treated in a variety of organ systems including the cardiovascular, gastrointestinal, endocrine, reproductive, and respiratory systems with emphasis on the central nervous system. Covers the mechanisms of action of drugs, and the influence of anatomy, physiology and pathology.

**Course directors:** Bronwen Connor & Mike Dragunow

**Assessment:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coursework</td>
<td>50%</td>
</tr>
<tr>
<td>Final exam</td>
<td>50%</td>
</tr>
</tbody>
</table>
### MEDSCI 700
**Drug Discovery Biology**
This course reviews recent studies on the use of chemical and genetic methods to characterise the role of proteins in disease and their potential as drug targets. Topics will include proteins involved in regulation of immune response, lipid mediated cell signalling pathways, drug-protein interactions, some discovery methods and pre-clinical studies on mechanism of action.

**Course Directors:** Jack Flanagan and Julie Spicer  
**Assessment:**  
- Course work 100%

### MEDSCI 701
**Special Studies in Medical Science**
Special topics in pharmacology may be arranged with the permission of the head of department after consultation with supervisor.

**Course Director:** Nuala Helsby  
**Assessment:**  
- Course work 100%

### MEDSCI 715
**Molecular Toxicology**
This course involves advanced study into the role of metabolism (including induction/inhibition and genetic polymorphisms) in the toxicity of xenobiotics and molecular events following exposure to toxic xenobiotics, such as mutagenesis, teratogenesis and apoptosis. The toxicity of several classes of drugs, including anticancer, antibacterial and antimalarial drugs is also studied in detail, as well as the application of toxicological principles in drug safety evaluation.

**Course Director:** Malcolm Tingle  
**Assessment:**  
<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project presentation and essay</td>
<td>40%</td>
</tr>
<tr>
<td>Final exam</td>
<td>60%</td>
</tr>
</tbody>
</table>

### MEDSCI 716
**Advanced Drug Disposition and Kinetics**
This course is concerned with the advanced study of the absorption, distribution, metabolism and excretion of drugs, in vivo and in vitro techniques for ADME studies, pharmacokinetics and pharmacogenomics in drug development.

**Course Director:** Stephen Jamieson  
**Assessment:**  
<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course work</td>
<td>30%</td>
</tr>
<tr>
<td>Final exam</td>
<td>70%</td>
</tr>
</tbody>
</table>

### MEDSCI 717
**Advanced Neuroscience: Neuropharmacology**
An advanced discussion of current research in neuroscience. The course will involve critical analysis of the literature within the context of a series of major research themes. Each theme will encompass models from molecular through to systems level neuroscience. In this course, themes will be selected from the following areas: neuroscience, neurodegeneration and addiction.

**Course Director:** Bronwen Connor  
**Assessment:**  
<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course work</td>
<td>30%</td>
</tr>
<tr>
<td>Final exam</td>
<td>70%</td>
</tr>
</tbody>
</table>

### MEDSCI 718
**Pharmacology of Anaesthetics & Analgesics**
This course deals with the general aspects of anaesthetics and analgesics. Topics covered include the development of modern anaesthesia, the mechanisms of action of drugs used in general and local anaesthesia, and issues surrounding safety and efficacy of anaesthesia, including drug error and circadian variation in drug action.

**Course Directors:** Guy Warman and James Cheeseman  
**Assessment:**  
<table>
<thead>
<tr>
<th>Component</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000 word essay</td>
<td>25%</td>
</tr>
<tr>
<td>Seminar presentation</td>
<td>5%</td>
</tr>
<tr>
<td>Final exam</td>
<td>70%</td>
</tr>
</tbody>
</table>
**MEDSCI 719**  
**Pharmacometrics**  
This course deals with the application of mathematical models to interpretation of pharmacological observations. Models provide an explanation for experimental observations as well as a description. Computer based analysis methods are used for individuals and populations. Typical areas of application are pharmacokinetics, pharmacodynamics, ligand binding, enzyme kinetics and time course of drug effect.  
**Course Directors:** Nick Holford and Jacqui Hannam  
**Assessment:**  
| Course work | 50% |
| Final exam  | 50% |

**MEDSCI 720**  
**Biomedical Research Techniques**  
Introduction to a broad base of research techniques ranging from tissue culture through microscopy to gene cloning and RNA interference. Emphasis is on theoretical basis, application and interpretation.  
**Course Director:** Debbie Young and Raewyn Poulsen  
**Assessment:**  
| Course work | 60% |
| Written test| 40% |

**MEDSCI 721**  
**Advanced Toxicology**  
The course addresses current issues and recent advances in toxicology. This course is aimed primarily at students wishing to undertake research in a field related to toxicology.  
**Course Director:** Malcolm Tingle  
**Assessment:**  
| Course work | 100% |

**MEDSCI 722**  
**Clinical Pharmacology**  
The course deals with the target concentration strategy and clinical pharmacokinetics; disease progress and variability in drug response; adverse drug reactions and evaluation of clinical trials. Drug disposition and action in the elderly, young and in pregnancy will also be considered. Emphasis is placed on the use of medicines in humans and application of clinical pharmacology to drug development.  
**Course Directors:** Nick Holford and Brian Anderson  
**Assessment:**  
| Course work | 30% |
| Final exam  | 70% |

**MEDSCI 723**  
**Cancer Pharmacology**  
The course focuses on the clinical pharmacology and development of drugs for treating cancer. The course deals with the main classes of anticancer drugs, including alkylating agents, platinum-based drugs, antimetabolites, topoisomerase-interactive drugs, antimicrotubule agents, targeted therapies and vascular targeting drugs. Other topics include the pharmacological basis of cancer chemotherapy, pharmacological variability and individualisation of cancer therapy, oncology clinical trials, drug interactions and combination chemotherapy, and selected research topics.  
**Course Director:** Mark McKeage  
**Assessment:**  
| Course work | 40% |
| Final exam  | 60% |
MEDSCI 735
Concepts in Pharmacology
The course explores the cellular and molecular mechanisms of drug action plus drug discovery and development from the perspective of in silico modelling, biochemical assessment, intracellular signalling and human disease. It considers the pharmacokinetic processes of input, distribution and elimination involved in achieving clinically-relevant drug concentrations. It also describes the link between concentration and effect and the time course of effect and explores factors such as disease progression, drug metabolism, drug-drug interactions, pharmacogenetics, use in selected populations and in various pathological conditions that may influence both clinical effectiveness and drug toxicity.

Course Director: Malcolm Tingle & Deanna Bell
Assessment:
- Written assignment: 15%
- Oral presentation: 15%
- Workshop participation: 20%
- Integrated written assignment: 50%

MEDSCI 744
Project Design in Biomedical Science
The course is targeted at potential masters students with the intention of developing ideas with a mentor around a research question that is then likely to become the basis of a masters research project. The written research proposal may have more resemblance to a grant application. It will include sections on background, proposed methods, ethical and regulatory considerations, a budget and the potential impact on health significance and/or translational potential to provide an understanding of the holistic requirements for biomedical research.

Course Director: Julie Lim and Scott Graham
Assessment:
- Preliminary proposal assignment: 10%
- Research proposal: 65%
- Oral presentation: 25%

MEDSCI 745
Special Topic: Drug Development
Examines approaches for bringing potential new therapeutic drugs from the discovery bench into the clinic and provides an introduction to the drug development process. Explores a variety of drugs and uses case studies to provide a practical understanding. Integrates multidisciplinary perspectives, drawn from academic and industry experiences, on practices that contribute to the development of safe and effective drug therapies. The course includes topics on pharmacology, drug disposition, drug delivery, safety, quality assurance & control in drug manufacturing, clinical trials, biomarkers and pharmacogenomics.

Course Director: Julie Spicer
Assessment:
- Article summary/presentation: 20%
- In-class assessment: 20%
- “Investor pitch” presentation: 20%
- Essay (3500 words): 40%
- NO EXAM

PHARMCOL 399
Capstone: Integrated Pharmacology
This student-led course uses the framework of an ethics application to explore how principles of pharmacology and toxicology inform the safe, effective and responsible use of drugs. Students discover how to apply their skills in experimental design, data collection, analysis and presentation with critical appraisal of the literature, as the scientific basis for rational, evidence-based decision-making.

Course directors: Rachel Cameron & Malcolm Tingle
Assessment:
- Coursework: 100%
Possible careers

The study of the way in which drugs work is the basis for a number of career possibilities. Some of these are briefly listed below and give examples of the opportunities available.

Teaching and Research in Higher Educational Institutions

In New Zealand, most teachers of pharmacology are concerned with training students for the medical, veterinary and pharmaceutical professions. Pharmacology is also taught to science students at the University of Auckland and University of Otago. It should be noted that appointment to a university teaching post usually requires the possession of a research degree or equivalent experience.

Biotechnology and Pharmaceutical Research and Development

The discovery and development of new and better medicines for the treatment of diseases in people and animals, as well as chemicals for food processing and agricultural application requires pharmacologists as part of the multi-disciplinary research and development teams. The pharmaceutical industry is a major source of employment opportunities but this mostly occurs overseas in Europe, the US and also Japan. In New Zealand pharmaceutical research is mainly confined to clinical trials with little basic pharmacological research being undertaken. However a number of small Biotech companies have started in New Zealand and offer some career opportunities. Pharmacologists can also find key roles in the medical, regulatory and marketing divisions of the pharmaceutical industry in New Zealand.

Clinical Teaching and Research

Medically qualified clinical pharmacologists are employed by pharmaceutical companies for evaluating drug activity in patients. In these studies, their work is supported by non-clinically qualified graduates and non-graduate technicians who contribute to the laboratory aspects of the clinical studies. Increasingly, more offices of multinational pharmaceutical companies and clinical research organisations are offering posts for clinical research assistants.

Government Department and Research Institutions

A number of opportunities are available for work in Government or government-sponsored research institutions. Examples of the type of work available are research and development studies, assessment of the cost and safety of medicines and advisory and safety aspects of chemicals used in the food processing and agricultural industries. In addition there are a number of research institutions and companies, such as the Auckland Cancer Society Research Centre (ACSRC) in Auckland, which is sponsored by the New Zealand Cancer Society, and the Malaghan Institute of Medical Research in Wellington which can provide research opportunities for pharmacologists.
Medical Publishing and Drug Information

A background in pharmacology and toxicology is ideal for entry into medical publishing and drug information dissemination. There are many opportunities in this expanding field. For example, Adis International is an international publishing and drug information company which has its headquarters at Mairangi Bay in Auckland.

Toxicology

A pharmacology/toxicology qualification is one of the principal entry routes into employment as a toxicologist. The training and ability to appreciate and measure the many aspects involved in the assessment of drug action and the adverse effects of chemicals forms an ideal basis for a career in toxicology. Toxicologists are employed in all the career categories mentioned above. The increasing use of food additives and agricultural chemical products, and increasing environmental hazards arising from pollution provide additional areas of career employment.

Privacy

The University of Auckland undertakes to collect, store, use and disclose your information in accordance with the provisions of the Privacy Act 1993. Further details of how the University handles your information are set out in a brochure available by phoning 0800 61 62 63.

Disclaimer

Although every reasonable effort is made to ensure accuracy, the information in this document is provided as a general guide only for students and is subject to alteration. All students enrolling at the University of Auckland must consult its official document, the current Calendar of the University of Auckland, to ensure that they are aware of and comply with all regulations, requirements and policies.

We advise that the University of Auckland is not involved in the employment of completing health professional students and can make no guarantee of post-qualification registration or employment in New Zealand or any other country.
# 2020 academic year

## Semester One – 2020

<table>
<thead>
<tr>
<th>Event</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semester One begins</td>
<td>Monday 2 March</td>
</tr>
<tr>
<td>Mid-semester break/Easter</td>
<td>Friday 10 – Monday 27 April</td>
</tr>
<tr>
<td>ANZAC Day</td>
<td>Monday 27 April</td>
</tr>
<tr>
<td>Graduation</td>
<td>Monday 4, Wednesday 6, Friday 8 May</td>
</tr>
<tr>
<td>Queen’s Birthday</td>
<td>Monday 1 June</td>
</tr>
<tr>
<td>Lectures end</td>
<td>Friday 5 June</td>
</tr>
<tr>
<td>Study break</td>
<td>Monday 8 – Wednesday 10 June</td>
</tr>
<tr>
<td>Examinations</td>
<td>Thursday 11 June – Monday 29 June</td>
</tr>
<tr>
<td>Semester One ends</td>
<td>Monday 29 June</td>
</tr>
<tr>
<td>Inter-semester break</td>
<td>Tuesday 30 June – Friday 17 July</td>
</tr>
</tbody>
</table>

## Semester Two – 2020

<table>
<thead>
<tr>
<th>Event</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semester Two begins</td>
<td>Monday 20 July</td>
</tr>
<tr>
<td>Mid-semester break</td>
<td>Monday 31 August – Friday 11 September</td>
</tr>
<tr>
<td>Graduation</td>
<td>Tuesday 22 September</td>
</tr>
<tr>
<td>Lectures end</td>
<td>Friday 23 October</td>
</tr>
<tr>
<td>Labour Day</td>
<td>Monday 26 October</td>
</tr>
<tr>
<td>Study break</td>
<td>Tuesday 27 – Wednesday 28 October</td>
</tr>
<tr>
<td>Examinations</td>
<td>Thursday 29 October – Monday 16 November</td>
</tr>
<tr>
<td>Graduation</td>
<td>TBC</td>
</tr>
<tr>
<td>Semester Two ends</td>
<td>Monday 16 November</td>
</tr>
</tbody>
</table>
Contact

Department of Pharmacology and Clinical Pharmacology
School of Medical Sciences
Faculty of Medical and Health Sciences
The University of Auckland
Private Bag 92019
Auckland 1142, New Zealand
Phone: +64 9 923 6733
Website: fmhs.auckland.ac.nz/sms/pharmacology